Close Menu

NEW YORK (GenomeWeb) – Curetis reported today that its revenues for the first nine months of 2017 dropped about 24 percent amid delays in some placements of its Unyvero molecular diagnostic system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.